Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 11/20 | 0.79 |
| ▸ | JAK2 | O60674 | 1/20 | 0.61 |
| ▸ | JAK3 | P52333 | 1/20 | 0.61 |
| ▸ | CAMK2D | Q13557 | 5/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7658943 | 0.92 | LCK (0.77) | LCKJAK2JAK3CAMK2DMKNK1 | |
| SCHEMBL7023829 | 0.91 | LCK (0.84) | LCKJAK2JAK3CAMK2DMKNK1 | |
| SCHEMBL7592510 | 0.91 | LCK (0.84) | LCKJAK2JAK3CAMK2DMKNK1 | |
| SCHEMBL7021042 | 0.89 | LCK (0.79) | LCKJAK2JAK3CAMK2DMKNK1 | |
| SCHEMBL7022093 | 0.88 | LCK (0.77) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7594220 | 0.88 | LCK (0.77) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7018359 | 0.88 | LCK (1.00) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7591189 | 0.88 | LCK (1.00) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7021167 | 0.88 | LCK (0.80) | LCKJAK2JAK3CAMK2DMKNK1 | |
| SCHEMBL7592839 | 0.88 | LCK (0.80) | LCKJAK2JAK3CAMK2DMKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1206265-B1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2003-11-12 | — | — | EP | disclosed |
| US-6498165-B1 | PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS | MERCK & CO., INC. | 2002-12-24 | — | — | US | disclosed |